Gastroenterology -Therapeutics & Hepatology

Therapies for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

Therapies for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) are an essential subject that focuses on the management of these rapidly emerging liver disorders. This interdisciplinary domain delves into the latest therapeutic strategies and treatment options to address the growing burden of NAFLD and NASH. The subject emphasizes the need for lifestyle modifications, including diet and exercise, as the cornerstone of NAFLD and NASH management. Moreover, it discusses the potential of pharmacological interventions, such as insulin sensitizers, antioxidants, and lipid-lowering agents, to target underlying metabolic abnormalities and liver inflammation. Additionally, the conference highlights emerging and investigational therapies, including novel agents that target fibrosis and inflammation, offering potential breakthroughs in treating advanced stages of NASH. By convening leading hepatologists, researchers, and pharmaceutical experts, the conference on Therapies for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis fosters interdisciplinary discussions and knowledge exchange. This subject aims to enhance the understanding and management of NAFLD and NASH, leading to improved patient outcomes and a potential reduction in liver-related morbidity and mortality.